Neurocrine Biosciences, Inc.
NBIX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | $209,500 | $107,500 | $7,900 | $103,100 |
| Dep. & Amort. | $7,700 | $7,300 | $7,600 | $7,100 |
| Deferred Tax | $168,300 | -$37,400 | -$13,700 | -$31,300 |
| Stock-Based Comp. | $53,700 | $52,800 | $52,800 | $66,400 |
| Change in WC | $62,800 | -$39,100 | -$23,700 | $94,300 |
| Other Non-Cash | -$274,500 | $10,900 | $33,900 | $2,900 |
| Operating Cash Flow | $227,500 | $102,000 | $64,800 | $242,500 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$13,200 | -$12,500 | -$10,700 | -$7,300 |
| Net Acquisitions | $0 | $0 | $0 | $0 |
| Inv. Purchases | -$408,500 | -$315,100 | -$273,200 | -$311,800 |
| Inv. Sales/Matur. | $225,000 | $298,600 | $298,100 | $250,800 |
| Other Inv. Act. | $0 | $0 | $0 | $0 |
| Investing Cash Flow | -$196,700 | -$29,000 | $14,200 | -$68,300 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $45,600 | $14,400 | $32,100 | $10,000 |
| Stock Repurch. | $0 | -$17,700 | -$150,000 | -$300,000 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $0 | $0 | $0 | $0 |
| Financing Cash Flow | $45,600 | -$3,300 | -$117,900 | -$290,000 |
| Forex Effect | -$200 | $200 | $0 | -$300 |
| Net Chg. in Cash | $76,200 | $69,900 | -$38,900 | -$116,100 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $272,000 | $202,100 | $241,000 | $357,100 |
| End Cash | $348,200 | $272,000 | $202,100 | $241,000 |
| Free Cash Flow | $214,300 | $89,500 | $54,100 | $235,200 |